X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Andrew Powaleny

Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly runs with the DC Front Runners and serves as its co-race director. He is also a member of the National Lesbian Gay Journalists Association and a proud alum of The Fund for American Studies. He’s passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.

Recent Posts

ICYMI: America’s biopharmaceutical companies are taking on COVID-19

By Andrew Powaleny  |    March 16, 2020
The biopharmaceutical industry is taking on COVID-19, a disease caused by a novel strain of coronavirus, through research and development (R&D) into prevention and treatment, in-kind financial...   Read More

Nearly 400 cell and gene therapies in development to target a broad range of diseases

By Andrew Powaleny  |    March 10, 2020
In 2017, the U.S. approved its first cell and gene therapy, making the idea of altering a gene to cure or treat a disease a reality. As the increasing pace of R&D propels cell and gene therapy...   Read More

ICYMI: Continued biopharmaceutical action on COVID-19

By Andrew Powaleny  |    March 6, 2020
Updated 3/11/2020 This week, PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss the industry’s response to COVID-19, a...   Read More

R&D Focus: New report shows nearly 600 medicines in development for pediatric patients

By Andrew Powaleny  |    February 13, 2020
America’s biopharmaceutical researchers are committed to studying, developing and testing medicines to meet the unique needs of pediatric patients. New treatment options for infants, children and...   Read More

ICYMI: 2019 brings innovative medicines to patients

By Andrew Powaleny  |    January 17, 2020
New reports from the U.S. Food and Drug Administration (FDA) show a total of 55 novel new medicines were approved in 2019. Among these, 48 were approved by the Center for Drug Evaluation and...   Read More

ICYMI: Cancer death rate declines at record levels thanks to innovative medicines

By Andrew Powaleny  |    January 9, 2020
Each year, the American Cancer Society estimates the number of new cancer cases and deaths that will occur in the United States. For nearly 30 years, the trend towards fewer cancer deaths has been...   Read More

R&D Focus: Four ways the biopharmaceutical industry leads in delivering new treatments and cures

By Andrew Powaleny  |    December 9, 2019
In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases,...   Read More

Event tomorrow: Maintaining America’s leadership in access and innovation

By Andrew Powaleny  |    October 16, 2019
Each year, biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high...   Read More

Nearly 140 medicines in development to treat mental illness

By Andrew Powaleny  |    October 10, 2019
Today is World Mental Health Day, a moment where we reflect about the challenges we still face towards better treatment of mental illness and its impact on patients.   Read More

IP Explained: Understanding biopharmaceutical innovation

By Andrew Powaleny  |    July 30, 2019
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates